BURBANK, CA–(Marketwire – November 29, 2010) – Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today provided insight into the Company’s strategy for resubmission to the FDA.

“After reviewing with our FDA counsel our prior application, files, images and recent FDA correspondence, Imaging3 plans to resubmit its application for clearance of the Dominion Vi Scanner under the FDA’s 510(k) process,” stated Dean Janes, Chairman and CEO of Imaging3, Inc. According to Mr. Janes, “The results of our review with counsel has determined that the 510(k) program remains the most appropriate and efficient route for FDA approval. It was determined that the ‘De Novo’ and ‘PMA’ processes were not necessary and with some minor adjustments to our existing package along with some additional information and potentially a pre-submission meeting with the FDA, the 510(k) submission should be successful. I am confident that with the assistance of our newly hired FDA consultants and our new strategy we will be able to provide the Agency with a package that meets their needs to expeditiously approve our device,” Mr. Janes added.

About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at www.imaging3.com

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

MANCHESTER, UNITED KINGDOM–(Marketwire – Nov. 29, 2010) – Bromsgrove based cosmetic surgery provider The Hospital Group, has announced the acquisition of Manchester based cosmetic surgery clinic, SurgiCare, after it bought the company out of administration.

The move secures The Hospital Group as the number one cosmetic surgery provider in Europe, with a network of 27 clinics situated across the UK and Ireland plus over 10 in Spain. The Group also expanded into the USA in 2009 with a base in Los Angeles.

Choosing to retain the SurgiCare brand independently, The Hospital Group and SurgiCare will tackle different areas of the market to gain a complimentary business strategy.

The deal has secured the jobs of 37 workers and follows the group’s recent acquisition of NU Age medical Spa in Newcastle Upon Tyne.

David Ross, Chief Executive at The Hospital Group, said: “This business deal shows the company’s commitment to consolidating and building our position in the UK and international market.

“Many people are struggling to find work in this tough economic climate but this partnership has helped to save jobs as well as open doors and create more opportunities.

“We are really excited about the potential that this opportunity has given us. There will doubtless be synergy and development on both sides.”

The Hospital Group are one of the UK’s leading providers of cosmetic surgery, providing cosmetic, dental and weight-loss solutions for thousands of patients every year. 

Since The Hospital Group was established in 1992, it has grown to become one of the world’s foremost cosmetic and weight loss surgery providers.

The flagship hospital, Dolan Park, is the largest specialist facility of its kind in the UK, dedicated to cosmetic and obesity surgery. All surgeons are GMC registered and cosmetic consultations are performed free of charge, with a lifetime free aftercare package included.

PALO ALTO, CA–(Marketwire – November 28, 2010) – Fovia, Inc., a leader in volume rendering technology, has demonstrated the scalability of its High Definition Volume Rendering® software on the newest generation of Apple® computers. Fovia’s HDVR® software performed 1.5x faster on a Mac Pro 12-core 2.93GHz than it did on a Mac Pro 8-core 2.93GHz (Apple’s previous generation), thereby showcasing perfect, core-for-core scalability. The benchmarking results can be found on Apple’s website at http://www.apple.com/macpro/performance.html.

Fovia’s HDVR algorithms and architecture take full advantage of the future directions in both imaging and computing (larger datasets, larger projection displays, multi-core processors, multi-threading, multi-CPU environments and server-side rendering for thin-clients) without sacrificing quality or performance. This scalability has been, and will continue to be, critical to ensuring the long-term superiority of Fovia’s solution. 

George Buyanovsky, Fovia’s President and C.T.O., remarked, “The highly-efficient multi-core scalability of HDVR has been a major focus of Fovia’s rendering technology. Our CPU-based Volume Ray Casting algorithms very effectively utilize available CPUs resources; therefore, the evolution of general purpose CPUs toward multi-cores and multi-threading are increasingly beneficial for our clients, and we are pleased that our benchmarking results have been published by such a well-respected third party.”

Fovia’s scalable, software-only solution has unparalleled interactive image quality, superior performance, and better memory utilization than other products currently available — including expensive, hardware-based approaches. In addition to its extraordinary scalability with respect to processor performance, Fovia’s HDVR® engine scales with both the exponentially increasing amount of data being generated by modern scanners, and with the continuing growth of larger and higher definition displays now being used for more accurate viewing.

About Fovia, Inc.

Fovia, Inc. was founded in 2003 to address the challenges of data explosion — the exponentially increasing amount of data being acquired by modern imaging modalities. The firm has developed a CPU-based, High Definition Volume Rendering® software solution that leverages and scales with multi-core, multi-processor and multi-threaded generational processor development. Fovia’s HDVR® solution is more scalable, cost effective, flexible, and easily deployable on an enterprise-wide basis than GPU or other hardware-based approaches and can be easily and natively integrated into various original equipment manufacturers’ offerings, therefore allowing OEMs to quickly and cost-effectively offer the world’s most advanced volume rendering to their customers.

For additional information, visit www.fovia.com.

Apple is a registered trademark of Apple Inc.

Fovia, High Definition Volume Rendering and HDVR are registered trademarks of Fovia Inc.

FOSTER CITY, CA–(Marketwire – November 27, 2010) – TeraRecon, Inc. (www.terarecon.com), a global leader in advanced visualization and decision support solutions, has received the North American Growth Leadership of the Year Award in the category of Advanced Visualization and Clinical Applications by the respected independent research firm Frost and Sullivan. This award represents the sixth time in the past 10 years that TeraRecon, Inc. has been recognized with an award from Frost and Sullivan. It is the second time in 2010, following the European Company of the Year Award in the category of Medical Imaging, Advanced Visualization Applications. The full text of the new award can be reviewed on the company’s website at www.terarecon.com/fs2010-2.pdf

The Award is issued contemporaneously with the release of the new Frost and Sullivan market research report on the North American advanced visualization market, and is derived from independent and objective research performed by the Frost and Sullivan team, which was not commissioned or funded by TeraRecon. The research was based on two independent primary research efforts conducted during the last year by Frost & Sullivan researchers, each focused on decision makers for advanced visualization in the United States.

Quoting from the text of the Frost and Sullivan award, “In more than one aspect, TeraRecon has become the leading independent vendor in the North American advanced visualization industry today.” The award noted that TeraRecon is “…capturing a higher market share than all other vendors within its tier of competition” and also recognized the company’s focus on the role and potential of advanced visualization in the healthcare enterprise: “Indeed, TeraRecon’s solutions achieve the highest ratings with regard to their remote access and integration capabilities, making TeraRecon the market leader for delivering advanced visualization enterprise-wide.”

The research also revealed that TeraRecon is perceived as the vendor offering the most advanced technology and the highest performance, that TeraRecon obtained the highest ratings for customer satisfaction, and that the surveyed respondents rated TeraRecon’s solution with the highest ratings for ease of use.

Frost and Sullivan made particular note of iNtuition™ CLOUD, stating “The cloud-based solution launched recently by TeraRecon is yet another illustration of the company’s edge with technology and its ability to react swiftly to emerging industry trends and customer needs.”

Furthermore, the value of the company’s investment in research and development of clinical applications was acknowledged with the observation that “TeraRecon achieved the highest ratings among independent vendors not only from a technology standpoint, but also from a clinical standpoint.”

TeraRecon President & CEO Robert Taylor, Ph.D. commented on the award, “We are truly honored to have received a sixth Frost and Sullivan award — the second within a single year, now recognizing the company’s achievements in the North American market, following up on the recognition we received from Frost and Sullivan earlier in the year relating to our innovative business strategy in Europe. This independent research by Frost and Sullivan objectively proves what we have always strived for relating to our customers’ appreciation of our products’ performance, our customer service, our clinical excellence, and our commitment to enterprise workflow and integration with other informatics systems. The accompanying report also highlights that TeraRecon’s enjoys the highest attachment and integration rate to PACS systems deployed in the North American market, as further evidence of the company’s commitment to a radiologist-centric workflow.”

Dr Taylor continued, “TeraRecon is more committed than ever to innovation and technological and clinical excellence. We are defining new boundaries for advanced visualization every day, as our new iNtuition CLOUD offering gains more and more registered users and the clinical capabilities of iNtuition expands rapidly. We believe that the future of medical imaging will inevitably consist of a combination of on-site software, cloud-based hosting, and meaningful integration with other enterprise healthcare informatics systems, and we embrace this challenge with the greatest enthusiasm and commitment.”

Free evaluation accounts for iNtuition CLOUD can be obtained at terarecon.com/cloud.

About TeraRecon (www.terarecon.com)
TeraRecon is a global leader in advanced image processing, decision support and 3D visualization techniques. The company’s solutions provide advanced imaging support for medical and other visualization applications based on its unique and patented image processing technologies. A six-time winner of Frost and Sullivan awards, the company has developed a leading portfolio of products that advance the performance, quality, functionality, and integration of image processing and 3D visualization systems since its founding in 1997. TeraRecon is a privately held company with headquarters in Foster City, California, USA, European headquarters in Frankfurt, Germany, and branch offices in Concord, Massachusetts, USA and Tokyo, Japan.

About Frost & Sullivan:
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com

iNtuition™ is a trademark of TeraRecon, Inc.

ALEXANDRIA, VA–(Marketwire – November 26, 2010) – Mortality rates for people with type 1 diabetes are decreasing, but overall remain seven times higher than those of the general population — likely as a result of long-term complications, a study in the December issue of Diabetes Care reports.

And while there were no significant differences in mortality rates between genders, women with type 1 diabetes were 13 times more likely to die than women who did not have diabetes, reported researchers from the University of Pittsburgh. Also in this study, part of the Epidemiology Research International Study Group, a much higher proportion of African Americans (50.6 percent) died than Caucasians (24 percent).

“It’s unclear why, for both women and African Americans, type 1 diabetes has such a major effect compared to the general population,” said Dr. Trevor Orchard, senior author of the study. “This greater effect of diabetes for women is not seen as strongly in studies in other parts of the world. One thing that is clear is that we need to pay special attention to their care and treatment and continue to investigate why they might be disproportionately impacted by the long-term consequences of this disease.”

Overall, mortality rates for people with type 1 diabetes fell significantly in this community-based population from Allegheny County, PA, over the past several decades, the study found. For those diagnosed between 1965 and 1969, mortality rates were 9.3 times higher than the general population. However, for those most recently diagnosed (1975-1979), the rate was just 5.6 times higher, showing a clear decline.

“It looks like the main improvement in those most recently diagnosed is related to dramatically reducing mortality in the first five years after diagnosis,” said Dr. Aaron Secrest, lead author of the paper. “We think it’s probably a result of better management and awareness of diabetes control, leading to providers and patients doing a better job of monitoring for acute complications.”

Overall, reductions in mortality are most likely due to the tremendous improvements in treatment and care during the 1980s and 1990s, the researchers noted. In particular, blood glucose self-monitoring, A1C testing and use of new blood pressure medications such as angiotensin-converting enzyme inhibitors, which also help protect against diabetic kidney disease. These changes have greatly improved both blood sugar and blood pressure control, often the cause of life-threatening complications.

The study looked at people in Allegheny County the Pittsburgh area who had type 1 diabetes diagnosed as a child between 1965 and 1979 and at the time of analysis had a duration of diabetes between 28 and 43 years, and explored differences in mortality based on sex, race (Caucasian vs. African American) and year of diagnosis.

For more information, please contact Dr. Trevor J. Orchard, University of Pittsburgh, Department of Epidemiology, Graduate School of Public Health, at email: [email protected] or call 412-383-1032.
To contact Dr. Aaron Secrest call 940-597-1991.

Diabetes Care, published by the American Diabetes Association, is the leading peer-reviewed journal of clinical research into one of the nation’s leading causes of death by disease. Diabetes also is a leading cause of heart disease and stroke, as well as the leading cause of adult blindness, kidney failure, and non-traumatic amputations.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Nov. 26, 2010) – The BC Medical Journal, BC doctors’ flagship medical journal, has completely revitalized its online presence. Beginning today, www.bcmj.org will not only continue with its tight focus on medical stories and advancements that occur in British Columbia, but will be adding the more dynamic qualities that the web is known for. 

BCMJ.org expanded upon its current website, which historically has simply provided the new monthly printed journal in an online method, by also including: 

• Video content linked to clinical articles in the journal that will incorporate related surgical videos and author interviews
• Health Notes for doctors and patients that will provide printable tips to improve your health on topics such as dealing with depression, reducing stress, and dementia, as well as reliable patient information related to clinical articles published in the BCMJ.
• Interactive content such as a blog in which physicians can interact with each other and members of the public and the ability to comment directly on published articles.
• A “people” section focusing on physician authors in the BCMJ, physicians who go above and beyond the call of duty, and stories about physicians’ own experiences in life.

“With the launch of our new website, the BCMJ takes giant leap forward in the brave new world of electronic communication. As the online home of BC physicians, we strive to keep doctors connected while providing them with fresh and relevant medical content,” says the BCMJ’s editor, Dr. David Richardson. 

The new interactive website is open to physicians in BC – and physicians around the globe – as well as all members of the public.

The British Columbia Medical Journal is a general medical journal featuring primarily scientific research, review articles, and updates on contemporary clinical practices written by British Columbian physicians or focused on topics likely to be of interest to them, such as columns from the BC Centre for Disease Control and ICBC. The print BCMJ is issued ten times each year, while bcmj.org will release stories throughout the month. The journal is peer reviewed and edited by an Editorial Board consisting of physicians from varying disciplines. Although it is published by the BC Medical Association (BCMA), it maintains distance from the BCMA in order to encourage open debate. It also hosts an online database for all BCMJ issues dating back to 2000.

LAS VEGAS, NV–(Marketwire – November 26, 2010) – Fresh Start (OTCBB: CEYY) announces it appointed Dr. Jorge Andres as CEO and Director of the company.

Effective November 22, 2010, Michael Cetrone resigned as President and Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and as a member of the Board of Directors of Fresh Start Private Management, Inc. (the “Company”).

Concurrent with Mr. Cetrone’s resignation, Dr. Jorge Adrade, was appointed Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer. Dr. Andrade was already a member of the Board of Directors of the Company.

Dr. Jorge Andrade Jr. is founder, CEO and President of West Coast Consulting Inc. since 2004. Dr. Andrade is a licensed Doctor of Dental Surgery and National Dental Board Certified since 1998. One of Dr. Andrade’s current positions is Senior Program Co-coordinator for the Western Division of Colgate Palmolive “Bright Smiles Bright Futures Dental Program.” Dr. Andrade is a Licensed Medical Interpreter, a licensed Doctor of Dental Surgery since 1995, and co-founder of TM Cube Medical LLC. Dr. Andrade has exceptional knowledge of starting, building and managing small businesses.

Effective November 22, 2010 the Board of Directors appoints Neil Muller as President.

Neil Muller is one of the world’s leaders in alcohol treatment and recovery and the architect of the Fresh Start Private Program. Mr. Muller has treated over 5,000 patients worldwide and will now focus his efforts on directing the clinics in America to cure the 18 million alcoholics across the country.

About Fresh Start Private™

Fresh Start Private is a company on the leading edge for the treatment of alcohol addiction. The Company’s founder has treated over 5,000 patients. Fresh Start is the only alcohol treatment program in the world to offer a single-administration, long acting, Naltrexone implant™. The non-invasive Naltrexone implant is placed just under the skin in the patient’s abdominal area. The procedure takes about 20 minutes and in nearly every instance patients are released the same day.

For more information, visit www.freshstartprivate.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission. 

TORONTO, ONTARIO–(Marketwire – Nov. 25, 2010) – Across Ontario, care for seniors is being compromised by a spate of hospital bed and program cuts and the transfer of elderly ill patients to sub-standard, unregulated care in retirement homes or to languish alone in their homes.

In Windsor, a 93 year old woman, who has two months to live, has been told to move out of the hospital or pay $600 a day to remain. She is the human face of elderly patients who are demeaned as “bed blockers.”

In Scarborough, Providence Continuing Healthcare is cutting 120 beds a move that will adversely affect many programs including patient rehab, and palliative and chronic care.

In Sudbury, the Regional Hospital’s Memorial site is closing—128 beds will be lost and frail seniors are being moved.

This pattern of hospital service cuts is happening across Ontario and services for the frail and the elderly are the primary target.

Across Ontario, home care is in chaos, with a 57% annual turnover of caregivers and with hours of care more and more difficult to access.

“We believe that the elderly are being discriminated against in the provision of care. Hospital, long- term care and home care workers have had enough of the attack on services for seniors. Our protest today is the beginning of our push back. We are asking for dignity in care for the elderly. We are asking for their right to spend their last days in palliative care in hospital. We demand an end to the pushing of the frail and the ill into unregulated retirement homes or to home alone,” says Michael Hurley, the president of the Ontario Council of Hospital Unions. 

Rally information is as follows:

Rally speakers include:

Paul Moist, President, Canadian Union of Public Employees, Arlene Patterson, Chair of the Sarnia Lambton Health Coalition, and hospital, long-term care and home care workers.

PANAMA CITY–(Marketwire – November 25, 2010) – The Stem Cell Institute (www.cellmedicine.com) reported today recovery of a spinal cord injury patient that was treated with a unique combination stem cell treatment. The patient suffered a crush fracture of the L1 vertebral body on May 13^th, 2008 after a single propeller engine airplane crash. As a result of the spinal cord injury, the patient had severe neuropathic pain, loss of sexual and bladder function, as well as loss of movement and sensation in the legs. 

He was treated on Oct 31-Nov 20, 2008, Jan 21-30, 2009, and July 1-10, 2009 with an adult stem cell protocol. The patient underwent a progressive recovery of sensation, mobility, and sexual and bladder function subsequent to each cycle of stem cell administration. Currently the patient is capable of walking and neuropathic pain diminished substantially.

“The doctors at the Stem Cell Institute have changed my life. After the accident there was no hope. Now I have a new lease on life,” said Juan Carlos Murillo Rodriguez, the patient who was treated. “I have recently passed my physical and am flying again as a commercial pilot.”

Details of the scientific rationale for the treatment, as well as protocols and outcomes may be found in the peer-reviewed paper “Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report” which was published in the International Archives of Medicine and is available online at http://www.intarchmed.com/content/pdf/1755-7682-3-30.pdf.

“It is my honor that such a team of internationally recognized opinion leaders in the area of stem cells such as Doctors Amit Patel, Michael Murphy and Thomas Ichim have co-authored this publication,” said Dr. Jorge Paz Rodriguez, Medical Director of the Stem Cell Institute and co-author of the publication. “By combining our clinical experience with cutting-edge advances in molecular and cellular biology, we believe we have put forth a very innovative protocol that we anticipate will be attempted by other groups.”

About Stem Cell Institute

Stem Cell Institute is one of the leading adult stem cell research and treatment centers in the world. Using our pioneering treatment methods and utilizing partnerships with universities and physicians across the world, Stem Cell Institute has already treated over 800 patients with stem cell therapy and the company continues to expand. Stem Cell Institute is located in Panama City, Panama.

id=”nav_links”>

TORONTO, ONTARIO–(Marketwire – Nov. 25, 2010) – With aging baby boomers making up nearly a third of Canada’s population, the $1.2 billion natural health product industry has naturally caught the eye of well known entrepreneur and strategic investor W. Brett Wilson. Through his involvement with Dragons’ Den, Wilson has committed to a $250,000 investment in NuvoCare Health Science Inc., a company with a portfolio of health brands designed to sustain youth and longevity and prevent disease.

The company was founded by Ryan J. Foley, a food scientist and pharmacologist who has designed a clinically proven composition called AgeOFF® designed to stop the DNA damage that leads to cancer and is the primary culprit behind human aging.

Having battled an advanced state of prostate cancer at 43, Wilson has made personal health his number-one priority, a core philosophy that is shared by NuvoCare. An estimated 173,800 Canadians will be diagnosed with cancer this year with approximately 76,200 of those cases resulting in death.

“This is as much a personal investment as a financial one,” said Wilson, who is also a daily product user. “I know too many people who are fighting cancer, and too many who have fought it and lost. It’s gratifying to support a company focused on reversing this negative trend.”

NuvoCare is also in conversations with the federal government to explore how their products can help reduce the upward pressure on federal-provincial health care spending, expected to grow significantly as more baby-boomers become seniors. On average, seniors consume five times more health-care dollars than younger adults. NuvoCare products help seniors stay healthy, decreasing their consumption of health-care dollars. The first baby-boomers will turn 65 on January 1, 2011.

“Brett has a passion for our work and a brilliant marketing mind able to help us reach more people and keep them healthy,” said Foley who added that NuvoCare is in a strong position to tap into a large percentage of Canada’s natural health product industry over the next three years.

NuvoCare was in established in 2006 by Foley after 10 years of corporate research and development experience in the nutraceutical industry. “I wanted to align myself with my higher life purpose of health sustainability and I built NuvoCare to realize this potential,” says Foley. NuvoCare’s products help to decrease body weight safely, prevent loss of muscle and bone, decrease the appearance of wrinkles and fine lines, and improve sleep quality, to name just a few of their benefits. NuvoCare’s portfolio of health brands includes AgeOFF® (www.AgeOFF.com), SleepON® (www.SleepON.com), WeightOFF® (www.WeightOFF.ca), DNA-Essentials® (www.DNAessentials.ca), and Skin-Minus® (www.SkinMinus.com).

NuvoCare Health Science Inc. is a Canadian owned and operated company whose sole focus is to design and develop the worlds safest and most effective nutraceutical, nutricosmetic, and cosmeceutical brands clinically proven to address the major health concerns of today’s consumer using proven natural ingredients of the highest safety, efficacy and quality standards. www.NuvoCare.com.

W. Brett Wilson is Chairman of Canoe Financial, a privately owned investment management firm with over $1.5 billion in assets focused on providing investors with unique opportunities to profit from Canada’s increasing prominence on the global stage. He is also Chairman of Prairie Merchant Corporation; a private merchant bank focused on business opportunities in the energy, agriculture, real estate, sports, and entertainment industries. In 1993, he co-founded FirstEnergy Capital Corp., a Canadian brokerage firm that provides investment-banking services to Canada’s oil and natural gas sector. FirstEnergy is an industry leader, having participated in thousands of financing and M&A projects worth over $225 billion. After retiring from active duty in 2008, Brett remains an investor in the firm.

NEW YORK, NY–(Marketwire – November 24, 2010) – Allied Healthcare International Inc. (NASDAQ: AHCI) will host a conference call and webcast to discuss the financial and operating performance for its fiscal 2010 fourth quarter and year ended September 30, 2010 on Tuesday, December 7, 2010, at 10:00 AM Eastern Time / 3:00 PM UK Time. The call will be hosted by Sandy Young, Chief Executive Officer, and Paul Weston, Chief Financial Officer. The Company will issue its earnings press release prior to the call.

Dial-In Information
Allied invites all those interested in listening to management’s discussion of the results to join the call by dialing (877) 407-8031 for domestic participants and (201) 689-8031 for international participants. Participants may also access a live webcast of the conference call through the “Investors” section of Allied Healthcare’s Website: www.alliedhealthcare.com. 

A telephone replay will be available for two weeks following the call by dialing (877) 660-6853 for domestic participants and (201) 612-7415 for international participants. When prompted, please enter account number 286 and conference ID number 360782. A webcast replay will also be available and archived on the Company’s website for ninety days.

ABOUT ALLIED HEALTHCARE INTERNATIONAL INC.
Allied Healthcare International Inc. is a leading provider of flexible healthcare staffing services in the United Kingdom. Allied operates a community-based network of approximately 115 branches with the capacity to provide carers (known as home health aides in the U.S.), nurses, and specialized medical personnel to locations covering approximately 90% of the U.K. population. Allied meets the needs of private patients, community care, nursing and care homes, and hospitals. For more news and information please visit: www.alliedhealthcare.com.

POWAY, CA–(Marketwire – November 24, 2010) – Lex Lee is a canine commemorative Purple Heart recipient who was a Marine Corps bomb-sniffing canine stationed in Fallujah. Lex survived a rocket-propelled grenade blast in March of 2007 that left him severely injured and took the life of his handler, Corporal Dustin J. Lee. 

Since that time, Lex has struggled with several problems related to his injuries including chronic arthritis. Dr. Lee Morgan of the Georgetown Veterinary Hospital teamed up with K9 Soldiers and Jerome and Rachel Lee in order to provide Lex with relief from the pain of his war injuries.

Dr. Morgan elected to use Vet-Stem Cell therapy to treat Lex’s arthritis and to hopefully regenerate damage from injuries sustained while serving in Fallujah. Dr. Morgan collected of a small amount of fat, sent it to Vet-Stem where the fat was processed, then Vet-Stem sent the isolated stem cells for injection two days later.

In honor of the contributions that Lex and the Lee family have made to the safety and freedom of people here and abroad, Vet-Stem will provide a free lifetime supply of Lex’s stem cells for as long as Lex might benefit from them. Approximately half the dogs treated with stem cell therapy will need to be re-treated within two years. Vet-Stem has over 18,000 doses of stem cells stored for thousands of animals and can create more by using stem cell culture technology. 

“We are pleased to be a part of this great effort and to do our small part in providing comfort to Lex and the Lee family and we appreciate Dr. Morgan’s contribution and discounted services,” says Vet-Stem Founder and CEO Robert Harman.

Dr. Morgan noted, “This is one of the most important patients that I have seen in 14 years of practice. I was surprised to see how quickly Lex was responding to the stem cell therapy. His owners and I are excited about the possibility of giving him an improved quality of life.”

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. In January of 2004, Vet-Stem introduced the first veterinary stem cell service in the United States. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. Vet-Stem has exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells.

Click here to see all recent news from this company

MADISON, WI–(Marketwire – November 24, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that President and CEO Fred Robertson, M.D., will participate in two upcoming investment community conferences.

On Tuesday, November 30, 2010, Dr. Robertson will present at the Piper Jaffray Healthcare Conference at 3:00 p.m. EST. The conference will be held November 30 – December 1 at The New York Palace hotel in New York City, NY. A live Webcast of the presentation will be available on the Investor Relations page of TomoTherapy.com. For those who are unable to listen to the live presentation, an archive of the Webcast will be available on the company’s site for 30 days following the presentation.

On Thursday, December 2, 2010, Dr. Robertson will attend the Lazard Capital Markets Med Tech/Life Sciences Tools Day, where he will be available for interviews throughout the day. The conference is being held at JW Marriott Denver Cherry Creek in Denver, Colo.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

(C)2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

FALLS CHURCH, VA–(Marketwire – November 24, 2010) – The Workgroup for Electronic Data Interchange (WEDI) and Accredited Standards Committee X12 (ASC X12), today released two documents, “Companion Guide Principles – Guidelines and Conventions for the Development of Proprietary Companion Guides to supplement published ASC X12 Implementation Guides” and the associated “Standard Companion Guide Transaction Information Template.”

The Principles Document clarifies the requirements for creating proprietary Companion Guides based on ASC X12’s published implementation guides. The Companion Guide Template is used to ensure a consistent look and feel with consistent content across the companion documents developed by various entities in the health care industry. 

A third document, the Communication/Connectivity Instructions template, is being finalized, and will be released soon.

Jim Schuping, Executive Vice President/CEO of WEDI, stated: “We are very pleased to have had the opportunity to collaborate with ASC X12 on the development and publication of these important documents. They will serve as a very useful tool and guideline to our respective memberships and the industry.”

“The Companion Guide Principles and Template documents will help several types of health care entities,” said Cathy Sheppard, Chair, ASC X12. “They will help those that create companion guides develop documents with all the needed information quickly and consistently and they will help those that use those companion guides by ensuring information from many sources has the same look and feel and the consistent content.”

You can download both of these free documents at http://store.x12.org/x12ip/cg.htm.

About WEDI
Workgroup for Electronic Data Interchange is a non-profit healthcare association dedicated to promoting the standardization of healthcare data and the implementation of administrative simplification in healthcare. WEDI’s membership includes providers, payers, integrated delivery networks, vendors, consumers, government organizations and standards groups. WEDI helped to secure the passage of the Health Insurance Portability and Accountability Act (HIPAA) in 1996, and was designated as an official Advisor to the Secretary in the legislation, acknowledging its influence and unique position in the healthcare industry. For additional information, visit www.wedi.org.

About ASC X12
ASC X12, chartered by the American National Standards Institute more than 30 years ago, develops and maintains EDI and CICA standards along with XML schemas which drive business processes globally. The diverse membership of ASC X12 includes technologists and business process experts, encompassing health care, insurance, transportation, finance, government, supply chain and other industries. For additional information, visit www.x12.org.

TORONTO, ONTARIO–(Marketwire – Nov. 24, 2010) – The Excellent Care for All Act (ECFAA) is the Ontario government’s first step in putting patients first by improving the quality and accountability of the province’s health care system. Health care providers and executives will be held directly accountable for patient safety and will have added responsibilities to ensure that the patient is at the centre of the health care system. They will be required to develop quality improvement plans and report to their boards on the progress they are making. To help ensure that this new act is implemented effectively, executive compensation will be linked to performance improvements and satisfaction surveys will be utilized to monitor progress.

According to Toronto Grace Health Centre’s Shirley Atkinson, current Chair of the Canadian Healthcare Risk Management Network, “Compliance with the Excellent Care for All Act is top of mind for all hospital boards, healthcare executives and quality and risk management leaders in Ontario. Electronic tools like ComplyTrack can help hospitals manage quality improvement plans and other requirements stemming from the Act, to reduce errors and improve overall performance.”

ComplyTrack, published by CCH (www.cch.ca), a part of Wolters Kluwer Law & Business, supports a compliance and risk management team’s efforts to standardize and/or eliminate manual and redundant processes, and can help to quantitatively demonstrate a process’ effectiveness to a health care facility’s management and board. Tools like ComplyTrack will be essential to the successful implementation of the quality improvement plans mandated by the ECFAA. 

About ComplyTrack

ComplyTrack is the #1 healthcare compliance and risk management software solution in North America, used by more than 1,000 hospitals. ComplyTrack delivers a comprehensive enterprise risk management software solution for the healthcare industry. It addresses 3 key problems:

• Which statutes, regulations, rules, best practices, standards and licensure requirements need to be complied with
• How to assess and quantify compliance with legislation, rules and best practices
• How to successfully manage and mitigate identified non-compliance and risk

For more information visit www.cch.ca/complytrack

About Wolters Kluwer Law & Business

Wolters Kluwer Law & Business is a leading provider of research products and software solutions in key specialty areas for legal and business professionals, as well as casebooks and study aids for law students. Its major product lines include MediRegs, Aspen Publishers, CCH, Kluwer Law International and Loislaw. Its markets include health care organizations, law firms, law schools, corporate counsel and professionals requiring legal and compliance information.

Wolters Kluwer is a leading global information services and publishing company providing products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion, employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.

LOS ANGELES, CA–(Marketwire – November 24, 2010) – On Location in Phoenix, medical equipment sales, shale gas in Bulgaria, rendering biomedical waste harmless; this week on MoneyTV with Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.

Free information packages from the featured companies can be requested by sending an email to [email protected].

The television program can also be viewed online immediately at www.moneytv.net.

Featured companies on this week’s program include:

Global Medical Equipment of America, Inc. CEO Harold Halman detailed the company’s business model of providing durable medical equipment through retail and wholesale channels.

Park Place Energy Corporation (OTCBB: PKPL) CEO David Johnson and Co-Founder/Consultant George Tsafalas announced the company’s operations in Bulgaria, discussed the shale gas industry and the company outlook going forward.

BioMedical Technology Solutions, Inc. (OTCBB: BMTL) CEO Donald Cox, Jr. demonstrated the company’s technology, which converts hazardous biomedical waste to simple trash.

MoneyTV debuted in 1996 and is broadcast internationally in more than 170 million TV households in over 60 countries.

A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net.

MoneyTV Executive Producer and Anchor Don Baillargeon is also the host of MoneyRap Radio, http://www.moneyrap.com and the television program Health This Week, http://www.healththisweek.com.

MoneyTV television program, Copyright MMX, all rights reserved. MoneyTV does not provide an analysis of companies’ financial positions and is not soliciting to purchase or sell securities of the companies, nor are we offering a recommendation of featured companies or their stocks. Information discussed herein has been provided by the companies and should be verified independently with the companies and a securities analyst. MoneyTV provides companies a 3 to 4 month corporate profile with multiple appearances for a cash fee of $11,500.00 to $17,250.00, does not accept company stock as payment for services, does not hold any positions, options or warrants in featured companies. The information herein is not an endorsement by Donald Baillargeon, the producers, publisher or parent company of MoneyTV.

Click here to see all recent news from this company

TAMPA, FL–(Marketwire – November 23, 2010) – Zimek Technologies, the industry leader in infection control and biohazard remediation, released its new corporate video which is available on the Zimek website (http://www.zimek.com/media.asp) or YouTube (http://www.youtube.com/watch?v=bGpOTrsTRQ8).

“Zimek’s new corporate video will allow visitors to gain a meaningful understanding of the ‘Perfect Storm’ of antibiotic-resistant microbes currently afflicting our society on a daily basis, and how Zimek’s technology is a vital part of the solution,” said Kurt Grosman, CEO of Zimek Technologies. “Zimek’s 21^st Century infection control technology has the ability to access infectious pathogens wherever free air flows in an enclosed environment. This is achieved with micro-droplets of EPA-registered disinfectants in sizes equivalent to bacteria, viruses, and fungi, thereby effectively killing and reducing the spread of infectious microbes before they infect their victims.”

Zimek’s corporate video also provides expert testimony by Brad Spellberg, MD, the highly-regarded infectious disease specialist, scientist, and researcher at the David Geffen School of Medicine at UCLA and Harbor/UCLA Medical Center in Los Angeles, California and author of “Rising Plague.” Additional footage is included from Zimek Advisory Board Members Hon. Emil Jones, Jr. and James Lee Witt, Florida Governor-Elect Rick Scott, and Zimek customers.

Zimek Technologies, based in Tampa, Florida, has been developing and marketing its patented automatic Micro-Mist^® decontamination technology for more than five years. Zimek’s industry-leading technology is used by the U.S. Department of Homeland Security, U.S. Department of Defense, U.S. Department of Veteran Affairs, fire and EMS departments, healthcare facilities, public health agencies, transit systems, correctional facilities, and local law enforcement agencies across America. For more information, please visit www.zimek.com.

NEW YORK, NY–(Marketwire – November 23, 2010) –  Cain Brothers & Company served Boston-based Caritas Christi Health Care (CCHC) as financial adviser in the recently completed successful sale to Steward Health Care System LLC (Steward), a newly formed affiliate of private equity firm Cerberus Capital Management, L.P. (Cerberus). Caritas and Cerberus announced that the transaction was completed on November 8, 2010. The system will continue to operate under the Caritas Christi banner and be led by CEO Dr. Ralph de la Torre and the current senior leadership team of CCHC.

The transaction represents the largest conversion of a not-for-profit health system to taxable status in Massachusetts’ history and the largest in the U.S. in many years. The transaction brings to CCHC approximately $895 million of new capital to be utilized for the assumption of pension obligations, repayment of debt, funding for operations, and significant capital projects. The CCHC hospitals will undergo major infrastructure improvements and benefit from significant investments in clinical technology and health care information technology.

Robert J. Fraiman, CEO of Cain Brothers and the leader of Cain Brothers’ transaction team, said, “We were pleased to assist Caritas CEO Ralph de la Torre, the Board of CCHC and the senior management team to complete this exceptional transaction. It is forward-looking in scope, and it will be good for the system and the communities and patients it serves. We are confident that Steward will be at the forefront of the trend towards community-based accountable care organizations (ACOs), which is driven by the health care reform legislation enacted earlier this year combined with the need for more efficient delivery of care to patients.”

Carsten Beith, Managing Director of Cain Brothers and leader of the firm’s tax-exempt merger and acquisition advisory service, said, “Although the Caritas-Cerberus transaction is unusually large, consolidation activity among hospitals and hospital systems is accelerating nationally. We expect to see a dramatic increase in the number of hospital M&A transactions among both not-for-profit and for-profit health care providers. The most significant factors leading to this activity include: capital markets that continue to be challenging, especially for providers that have significant capital improvement needs, as well as health care reform, with its heavy information technology requirements and the need better manage the risks of utilization and outcomes, while providing increased transparency for both patients and regulators.”

Cain Brothers is a leading investment banking firm that focuses exclusively on the health care industry. The firm’s clients include investor-owned and tax-exempt providers, payors, health care information technology and medical technology companies, and financial sponsors. The firm has one of the largest teams of experienced bankers and capital markets professionals on Wall Street dedicated to the health care industry. Operating out of nine offices across the country, the firm creates custom-tailored, market-based capital raising, M&A, real estate, and strategic and financial advisory solutions for its clients. 

UTICA, NY–(Marketwire – November 23, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company will participate in the 22^nd Annual Piper Jaffray Health Care Conference, on Wednesday, December 1, 2010 at 11:00 AM Eastern time. The event will be held in New York at the New York Palace Hotel.

Mr. Joseph J. Corasanti, President and Chief Executive Officer of CONMED, will discuss the Company’s business. The live webcast of CONMED’s presentation will be available at www.conmed.com in the Investor Relations – Events Calendar section of the website and will be available for replay through December 10, 2010.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

Certain statements made in the presentation may constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. They will be based upon management’s expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management’s assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; and/or (viii) the Company’s ability to devise and execute strategies to respond to market conditions.

MADISON, WI–(Marketwire – November 23, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced availability of a shielding solution that enables hospitals and cancer centers to quickly, easily and inexpensively build out treatment vaults that are properly shielded for use of the TomoTherapy^® radiation therapy system. The Total Shield^™ by NELCO, the worldwide leader in designing, manufacturing, and installing specialized products and services for the medical, industrial, and construction fields, is a customized shielding enclosure designed to fit around a TomoTherapy unit, making it possible for the radiation therapy system to be placed into existing under-shielded vaults or other treatment rooms where there may not be enough space to install necessary shielding using the existing infrastructure.

Total Shield provides hospitals and cancer centers with the flexibility to put the TomoTherapy system in an existing space, which may be too small or may not include enough shielding for modern intensity-modulated radiation therapy (IMRT) devices. Instead of adding shielding in the walls, the Total Shield enclosure is designed to wrap around the TomoTherapy system itself.

By taking this approach, TomoTherapy customers can potentially save hundreds of thousands of dollars in shielding costs and eliminate the months it takes to install conventional shielding solutions. Total Shield can be installed in just a matter of days. Additionally, because the Total Shield can be easily removed, it can be reused if the TomoTherapy system is eventually moved to a new location.

“Total Shield is the most recent example of how the TomoTherapy system’s unique design, and its small footprint, can allow hospitals and cancer centers to easily adopt cutting-edge cancer care technology in places where other solutions are not feasible,” said Harry Freeman, director of commercial operations at TomoTherapy. “Combined with the TomoTherapy system’s integrated beam stop technology, Total Shield can dramatically reduce the cost of building out a vault with extensive shielding, and enables facilities to get their TomoTherapy system up and running much quicker than other radiation treatment solutions.”

Total Shield was designed collaboratively by NELCO and will be on display in the TomoTherapy booth (#6406) at RSNA 2010, November 28 – December 3, at McCormick Place in Chicago, Illinois.

About NELCO 
NELCO, an ISO 9001:2008 certified company, is an industry leader in the design, manufacturing, and installation of specialized products and services, for the medical, industrial, and construction fields. Such products include shielding for medical radiation therapy, medical diagnostic imaging, anti-corrosive linings, and industrial radiation shielding. With offices around the US, United Arab Emirates, the United Kingdom and China, NELCO always has a facility nearby, cutting shipping costs, and helping excel in customer service. For more information, visit http://www.nelcoworldwide.com, or call 1-781-933-1940.

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions includes its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoHD, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

LOS ANGELES, CA–(Marketwire – November 23, 2010) – Fresh Start Private Management Inc. (OTCBB: CEYY), a leader in the alcohol treatment and rehabilitation industry, today announced that it has entered into an agreement with Fresh Start Private Inc. that was subsequently filed as an 8K with the SEC.

Under the terms of the agreement, Fresh Start Private Management, Inc. (FSPM) has entered into an Intellectual Property License and Asset Purchase Agreement with Fresh Start Private Inc., a private Nevada Company in the alcohol treatment business.

Under the terms of the Agreement FSPM will own all assets and have exclusive rights in the United States of America for Fresh Start Private Inc.’s alcohol treatment program and methodology.

See the 8K filed with the SEC for more information.

About Fresh Start Private
Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of addiction treatment. The Company has developed a patented highly effective treatment delivers target therapeutic levels of Naltrexone that significantly reduce patients’ cravings for alcohol. To date, more than 5,000 patients have received the Fresh Start Private Naltrexone implant.

For more information visit www.freshstartprivate.com

The information in this release includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Although the company believes that its expectations are based on reasonable assumptions, actual results may differ materially. These forward-looking statements involve risks and uncertainties that include, among others, market demand for, and/or available supplies of products and services; unanticipated delays, risks related to competition, management of growth, new products, services and technologies, potential fluctuations in operating results, commercial agreements, acquisitions and strategic transactions, government regulation and taxation. More information about factors that potentially could affect the Company’s financial results is included in its filings with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.